Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

​Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents.

The company made strides in gaining regulatory approvals, including Medicare coverage for its Guardant Reveal Smart Liquid Biopsy, a platform for colorectal cancer surveillance. Strategic ...

"Last month, we were pleased to receive Medicare reimbursement for Guardant Reveal in the CRC surveillance setting, which was an important milestone for our MRD business. We are entering 2025 with ...

Guardant Health reported strong Q4 2024 results ... and leveraging reimbursement tailwinds for Reveal. With a robust revenue outlook for 2025 and continued operational improvements, the company ...

The company is expanding its Medicare coverage for Guardant Reveal, its liquid biopsy test for monitoring disease recurrence in patients with colorectal cancer. Guardant Health, Inc. (NASDAQ ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with expanded ...

In January, Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for ...